MOLN MOLECULAR PARTNERS AG

NEUTRAL Impact: 3/10 6-K
Horizon months Filed Mar 30, 2026 Processed 1mo ago SEC 0001745114-26-000015
Notable filing: 6-K
Latest settled — T+20d
MOLN ▲ +8.91% at T+20d
NEUTRAL call ✓ call won +8.91% · α vs SPY -3.69% · entry $3.93 → $4.28
Next anchor: T+60d in 5w
Currently $3.70 · -5.85% from $3.93 entry
Entry anchored
Mar 27, 11:32 AM ET
via Databento tick
T+1d
+0.99%
call +0.99% · α -1.90%
$3.97
settled 7w ago
T+5d
-1.53%
call -1.53% · α -5.83%
$3.87
settled 6w ago
T+20d
+8.91%
call +8.91% · α -3.69%
$4.28
settled 23d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Molecular Partners AG announced the nomination of Clare Fisher for election to its Board of Directors at the upcoming 2026 Annual General Meeting, while current board member Steven H. Holtzman will not seek re-election after 12 years of service. The filing is a routine corporate governance update with no material financial implications.

Actionable Insight

This is a routine governance update. Traders should monitor the company's upcoming Interim Management Statement on May 12, 2026, for potential operational or financial updates. The addition of Clare Fisher, with her biotech business development background, may support future partnership efforts, but no immediate impact is expected.

Key Facts

  • Clare Fisher, currently SVP for Global Business Development at BeOne Medicines, has been nominated for election to the Board of Directors.
  • Steven H. Holtzman is stepping down after 12 years on the Board and will not stand for re-election.
  • The Annual General Meeting is scheduled for April 14, 2026, in Schlieren, Switzerland.
  • No financial terms, strategic shifts, or operational updates were disclosed in the filing.

Financial Impact

No immediate financial impact. Board composition changes are routine and do not affect capital structure or cash flow.

board compositiongovernance

Risk Factors

  • Change in board leadership could lead to strategic shifts over time, though no such indication is present in this filing.
  • No material information was provided that would alter near-term investment thesis.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001745114-26-000015
Document: molecularpartners-form6xkm.htm0001745114-26-000015
Document: 0001745114-26-000015-index-headers.html0001745114-26-000015
Document: 0001745114-26-000015-index.html0001745114-26-000015
Document: 0001745114-26-000015.txt0001745114-26-000015
4 reports for MOLN
Performance horizon
Filters
Rows
Reports for MOLN — sortable, filterable
Type Now
May 12, 2026
8d ago
6-K
NEUTRAL ★ 5/10
$4.00 $3.74▼ −6.50%▼ −5.34%$3.70 (−7.50%)
May 1, 2026
20d ago
Press Release
NEUTRAL ★ 4/10
$4.24 $4.10▼ −3.30%▼ −5.65%$3.70 (−12.74%)
Mar 30, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$3.93 $3.87▼ −1.53%▼ −5.83%$3.70 (−5.85%)
Mar 12, 2026
9w ago
Press Release
MIXED ★ 6/10
$4.22 $4.59▲ +8.65%▲ +10.77%$3.70 (−12.32%)
Showing 4 of 4

US Market Status

Market Open — Closes in 3h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access